Monday, 17 August 2026European Markets
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Platforms Move to Shore Up Trust as Leadership Shifts and AI-Adjacent Markets Wobble
Major AI and media platforms are converging on trust and accountability measures — Anthropic's Claude adding watermarks, Spotify labeling AI artists — just as OpenAI loses special-projects lead Brad Lightcap and Meta's Zuckerberg publishes a defensive manifesto on AI's societal role. In parallel, AI-adjacent financial dynamics are surfacing real stress: Wall Street firms are paying for privileged early access to Trump's Truth Social posts for trading edge, while Trump Media itself reports a $238M loss driven by falling crypto holdings, highlighting how information asymmetry and speculative digital assets are becoming entangled with AI-era platforms.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,809
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,809 facts checked against source5,205 source documents archived
Work with this data → vianewsagency.com

SEQUANA MEDICAL Stock Bearish Momentum With A 28% Slide So Far On Tuesday

Loading stream...

(VIANEWS) - Shares of SEQUANA MEDICAL (BEL 20: SEQUA.BR) dropped by a staggering 28.46% to €3.62 at 11:21 EST on Tuesday, after two consecutive sessions in a row of losses. BEL 20 is sliding 0.64% to €3,808.21, after two sequential sessions in a row of gains. This seems, up to now, a somewhat down trend exchanging session today.

SEQUANA MEDICAL's last close was €5.00, 33.33% below its 52-week high of €7.50.

About SEQUANA MEDICAL

Sequana Medical NV, a commercial stage medical device company, engages in the development of platform for the treatment of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; Direct Sodium Removal (DSR) for the treatment of persistent congestion due to heart failure; and alfapump DSR, a fully implanted system for direct sodium removal therapy in patients with fluid overload due to heart failure. It operates in Belgium, Germany, France, Switzerland, and internationally. The company was founded in 2006 and is headquartered in Ghent, Belgium.

Earnings Per Share

As for profitability, SEQUANA MEDICAL has a trailing twelve months EPS of €-1.29.

Revenue Growth

Year-on-year quarterly revenue growth grew by 31.8%, now sitting on 923k for the twelve trailing months.

Yearly Top and Bottom Value

SEQUANA MEDICAL's stock is valued at €3.62 at 11:21 EST, way under its 52-week low of €4.82.

Moving Average

SEQUANA MEDICAL's worth is way below its 50-day moving average of €5.31 and way below its 200-day moving average of €5.90.

More news about SEQUANA MEDICAL (SEQUA.BR).